CancerDrs

Colorectal Cancer clinical trials in Florida

90 actively recruiting colorectal cancer trials at 53 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Florida:
  • AdventHealth Altamonte — Altamonte Springs, Florida
  • AdventHealth Celebration — Celebration, Florida
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Florida:
  • Schulze Family Foundation Cancer Clinic - Bonita Health Center — Bonita Springs, Florida
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • Regional Cancer Center-Lee Memorial Health System — Fort Myers, Florida
Phase 3 Recruiting Industry

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Florida:
  • Mount Sinai Medical Center Aventura ER — Aventura, Florida
  • Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
  • Mount Sinai Medical Center — Miami Beach, Florida
Phase 3 Recruiting Industry

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …

Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Florida:
  • Florida Cancer Specialists — Bonita Springs, Florida
  • Florida Cancer Specialists — Bradenton, Florida
  • Florida Cancer Specialists — Cape Coral, Florida
  • BRCR Global - Coral Springs — Coral Springs, Florida
  • Florida Cancer Specialists — Fort Myers, Florida
Phase 3 Recruiting Network

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Florida:
  • Orlando Health Cancer Institute — Orlando, Florida
Phase 3 Recruiting Industry

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Florida:
  • Florida Cancer Specialists South — Fort Myers, Florida
  • AdventHealth Medical Group Oncology and Hematology at Orlando — Orlando, Florida
  • Florida Cancer Specialists North Region — St. Petersburg, Florida
  • Florida Cancer Specialists East — West Palm Beach, Florida
Phase 3 Recruiting Network

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Industry

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…

Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Florida:
  • Clinical Study Site — Hialeah, Florida
  • Clinical Study Site — Miami, Florida
  • Clinical Study Site — Orlando, Florida
  • Clinical Study Site — Plantation, Florida
  • Clinical Study Site — Port Saint Lucie, Florida
Phase 2, Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Florida:
  • Florida Cancer Specialists - East — Cape Coral, Florida
  • Florida Cancer Specialists - North — St. Petersburg, Florida
  • Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…

Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Florida:
  • GSK Investigational Site — Deerfield Beach, Florida
  • GSK Investigational Site — Fort Lauderdale, Florida
Phase 3 Recruiting Industry

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…

Sponsor: Amgen
NCT ID: NCT06252649
Sites in Florida:
  • Cancer Specialists of North Florida - Southpoint — Jacksonville, Florida
  • D and H Cancer Research Center — Margate, Florida
  • Mid Florida Hematology and Oncology Centers PA — Orange City, Florida
  • Boca Raton Clinical Research Medical Center Inc — Plantation, Florida
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Florida:
  • Florida Cancer Specialists - South ( Site 7002) — Fort Myers, Florida
  • Orlando Health Cancer Institute ( Site 0065) — Orlando, Florida
  • Florida Cancer Specialists - North ( Site 7001) — St. Petersburg, Florida
  • Florida Cancer Specialists - East ( Site 7000) — West Palm Beach, Florida
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Florida:
  • Memorial Healthcare System — Hollywood, Florida
  • Local Institution - 2113 — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Florida:
  • Florida Cancer Specialists — Fort Myers, Florida
  • Mayo Clinic (Florida) — Jacksonville, Florida
  • Cancer Specialists of North Florida — Jacksonville, Florida
  • Florida Cancer Specialists — Orlando, Florida
  • Florida Cancer Specialists — Sarasota, Florida
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Florida:
  • University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
  • Advent Health — Orlando, Florida
  • Florida Cancer Specialists South — Port Charlotte, Florida
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Florida:
  • Mayo Clinic Cancer Center — Jacksonville, Florida
  • Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…

Sponsor: Eli Lilly and Company
NCT ID: NCT04956640
Sites in Florida:
  • AdventHealth Orlando — Orlando, Florida
  • Florida Cancer Specialists — Sarasota, Florida
Phase 2 Recruiting Industry

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Colorectal Cancer Undergoing Chemotherapy

This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed locally advanced, unresectable or metastatic colorectal cancer. This study w…

Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Florida:
  • Investigative site — Coral Springs, Florida
  • Investigative Site — Hialeah, Florida
  • Investigative Site — Margate, Florida
  • Investigative Site — Miami Beach, Florida
  • Investigative Site — Tamarac, Florida
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…

Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Florida:
  • Mayo Clinic Hospital Jacksonville /ID# 274472 — Jacksonville, Florida
  • Moffitt Cancer Center /ID# 274372 — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Florida:
  • Florida Cancer Specialists — Sarasota, Florida
  • Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Florida:
  • AdventHealth Celebration — Celebration, Florida
  • University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 2 Recruiting Industry

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Florida:
  • Florida Cancer Specialists - South — Fort Myers, Florida
  • Florida Cancer Specialists - Lake Nona — Orlando, Florida
  • Florida Cancer Specialists - North — St. Petersburg, Florida
  • Florida Cancer Specialists - East — West Palm Beach, Florida

Showing 25 of 90 trials with sites in Florida. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25